Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults (DHEA-HTAP)
Sponsor: University Hospital, Bordeaux
Summary
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in human. The purpose of this study is to determine if DHEA is effective in the treatment of respiratory pulmonary hypertension in adults with Chronic Obstructive Pulmonary Disease (COPD) on exercise capacity and haemodynamic variables. Patients will receive after randomisation either 25 mg/day or 200mg/day oral DHEA over a one-year period. Evaluation concerns clinical parameters, echocardiography and right catheterization after and before treatment. Primary end-point is the six-minute walk test. This is a prospective double blind, randomised, placebo controlled study which will be realized in four university hospitals in France : Bordeaux, Strasbourg, Toulouse and Limoges.
Official title: Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults. Phase 2 Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
51
Start Date
2008-05-06
Completion Date
2015-06-05
Last Updated
2026-06-11
Healthy Volunteers
No
Interventions
DHEA Treatment
DHEA : 200 mg/day hard gelatine capsule
DHEA Treatment
DHEA : 25 mg/day hard gelatine capsule
Locations (4)
University Hospital, Bordeaux
Bordeaux, France
CHU de Limoges
Limoges, France
CHU de Strasbourg
Strasbourg, France
CHU de Toulouse
Toulouse, France